Seagen Inc SGEN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 12:41 PM EST
152.02quote price arrow up+0.91 (+0.60%)
Volume
558,821
52 week range
90.57 - 213.94

...

Loading . . .

KEY STATS

  • Open152.21
  • Day High153.48
  • Day Low150.58
  • Prev Close151.11
  • 52 Week High213.94
  • 52 Week High Date10/13/20
  • 52 Week Low90.57
  • 52 Week Low Date03/16/20
  • Market Cap27.54B
  • Shares Out181.16M
  • 10 Day Average Volume1.36M
  • Dividend-
  • Dividend Yield-
  • Beta0.95
  • 1 Year % Change33.53

RATIOS/PROFITABILITY

  • EPS (TTM)3.30
  • P/E (TTM)46.13
  • Fwd P/E (NTM)-171.39
  • EBITDA (MRQ)649.242M
  • ROE (MRQ)22.88%
  • Revenue (MRQ)2.176B
  • Gross Margin (MRQ)89.99%
  • Net Margin (MRQ)28.21%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date04/28/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Seagen Inc News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Seagen Inc., formerly Seattle Genetics, Inc., is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company is commercializing ADCETRIS or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain...
Clay Siegall Ph.D.
Chairman
Todd Simpson CPA
Chief Financial Officer
Vaughn Himes
Chief Technology Officer
Jean Liu J.D.
Executive Vice President
Address
21823 30th Dr SE
Bothell, WA
98021-3907
United States